These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 34108743)

  • 41. A comparison of two methods for estimating the technical costs of external beam radiation therapy.
    Hayman JA; Lash KA; Tao ML; Halman MA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):461-7. PubMed ID: 10802374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.
    Brown ML; Riley GF; Potosky AL; Etzioni RD
    Med Care; 1999 Dec; 37(12):1249-59. PubMed ID: 10599606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored.
    Blackhouse G; Briggs AH; O'Brien BJ
    Med Decis Making; 2002; 22(2):173-7. PubMed ID: 11958499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
    Latimer NR; White IR; Abrams KR; Siebert U
    Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using inverse-weighting in cost-effectiveness analysis with censored data.
    Willan AR; Lin DY; Cook RJ; Chen EB
    Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimating health care costs related to cancer treatment from SEER-Medicare data.
    Brown ML; Riley GF; Schussler N; Etzioni R
    Med Care; 2002 Aug; 40(8 Suppl):IV-104-17. PubMed ID: 12187175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A regression-based method for estimating mean treatment cost in the presence of right-censoring.
    Carides GW; Heyse JF; Iglewicz B
    Biostatistics; 2000 Sep; 1(3):299-313. PubMed ID: 12933511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
    Willems S; Schat A; van Noorden MS; Fiocco M
    Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.
    Shei A; Rice JB; Kirson NY; Bodnar K; Enloe CJ; Birnbaum HG; Holly P; Ben-Joseph R
    J Manag Care Spec Pharm; 2015 Oct; 21(10):902-12. PubMed ID: 26402390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Evaluation of the burden of diabetes in Poland].
    Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.
    Rutstein SE; Siedhoff MT; Geller EJ; Doll KM; Wu JM; Clarke-Pearson DL; Wheeler SB
    J Minim Invasive Gynecol; 2016 Feb; 23(2):223-33. PubMed ID: 26475764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evaluation of the data collection process for a multicenter, population-based, case-control design.
    Wingo PA; Ory HW; Layde PM; Lee NC
    Am J Epidemiol; 1988 Jul; 128(1):206-17. PubMed ID: 3381827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2007 rates; fiscal year 2007 occupational mix adjustment to wage index; health care infrastructure improvement program; selection criteria of loan program for qualifying hospitals engaged in cancer-related health care and forgiveness of indebtedness; and exclusion of vendor purchases made under the competitive acquisition program (CAP) for outpatient drugs and biologicals under part B for the purpose of calculating the average sales price (ASP). Final rules and interim final rule with comment period.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2006 Aug; 71(160):47869-8351. PubMed ID: 16921666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Causal mediation analysis on failure time outcome without sequential ignorability.
    Zheng C; Zhou XH
    Lifetime Data Anal; 2017 Oct; 23(4):533-559. PubMed ID: 27464958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonignorable censoring in randomized clinical trials.
    Zhang J; Heitjan DF
    Clin Trials; 2005; 2(6):488-96. PubMed ID: 16422309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.